PDS Biotechnology AI Stock Analysis
PDS Biotechnology (EU6) AI Stock Analysis
PDS Biotechnology
(Frankfurt:EU6)
No summary available
PDS Biotechnology (EU6) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 43.39M
- Dividend Yield
- ―
- Average Volume (3M)
- 8,848
- Price to Earnings (P/E)
- -1.4
- Beta (1Y)
- 0.64
- Revenue Growth
- ―
- EPS Growth
- 35.78%
- Country
- Germany
- Employees
- 21
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
PDS Biotechnology Business Overview & Revenue Model
Company Description
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical tria...
PDS Biotechnology Earnings Call Summary
The call conveyed meaningful clinical and intellectual property progress: a strategic protocol amendment for VERSATILE-003 that reduces patient count (~28.6%) and time to an interim readout, peer-reviewed and encouraging clinical data for PDS01ADC, strengthened IP extending PDS0101 protection into the 2040s, and established manufacturing processes. Financially, operating expenses and net loss improved year-over-year. Key risks include a relatively modest cash balance ($21.7M), continued unprofitability with rising interest expense, the need for OS data for full approval and additional confirmatory trials, and competition in the HPV16 head and neck space. On balance, the operational and clinical positives outweigh the near-term financial and development risks.
Q1-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided that the VERSATILE‑003 amendment adopts progression‑free survival as an interim co‑primary endpoint (retaining overall survival for full approval) to enable a potential accelerated approval, changes randomization from 2:1 to 1:1 and reduces planned enrollment from ~350 to ~250 patients to shorten duration, lower external and internal costs and speed an interim readout (sites remained engaged and enrollment is restarting); they reiterated PDS0101’s differentiators (only late‑stage HPV16 HNSCC regimen that is subcutaneous and requires just five doses) and noted new U.S. and Japanese patents extending PDS0101 market protection into the 2040s. Financial metrics include cash of $21.7M as of March 31, 2026, a Q1 net loss of ~$7.3M ($0.13 per share) versus $8.5M ($0.21) year‑ago, R&D of $3.5M (vs $5.8M), G&A of $3.1M (vs $3.3M), total operating expenses of $6.5M (vs $9.1M) and net interest expense of $0.8M (vs $0.6M); operational guidance also highlighted an established Versamune manufacturing process with CMC validation/scale‑up ahead of a BLA and that PDS01ADC data (JCO Oncology Advances, NCI/AACR) support advancement—colorectal Stage 2 is fully enrolled with additional data expected by year‑end.
PDS Biotechnology Risk Analysis
PDS Biotechnology disclosed 52 risk factors in its most recent earnings report. PDS Biotechnology reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksPDS Biotechnology Peers Comparison
Overall Rating
LTRN40Underperform
CALC39Underperform
SNTI39Underperform
TPST38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 40Underperform | $4.51M | -0.21 | -674.37% | ― | ― | 32.93% | |
| 39Underperform | $8.07M | -0.28 | -3029.57% | ― | ― | 45.29% | |
| 39Underperform | $7.25M | -0.04 | 3547.64% | ― | ― | 56.67% | |
| 38Underperform | $6.12M | -0.07 | -3552.74% | ― | ― | 61.31% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:EU6 | Pds Biotechnology | 0.69 | 0.04 | 6.28% | |
| TPST | Tempest Therapeutics, Inc. | 0.29 | -3.88 | -93.12% | |
| LTRN | Lantern Pharma, Inc. | 0.24 | -3.13 | -92.73% | |
| CALC | Calcimedica, Inc. | 1.26 | -19.69 | -93.99% | |
| SNTI | Senti Biosciences, Inc. | 1.77 | -67.20 | -97.43% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
